GlassScriptPhysician profile
Kandice Burk
NPI 1902371925
$2,648.94
in general payments reported to CMS, 2019-2025
29 companies · $693 in 2025
The $693 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $359 · 2022: $839 · 2023: $460 · 2024: $298 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,451.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $443.65 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $243.71 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Otsuka America Pharmaceutical, INC. | $228.73 | 2021-2025 | Rexulti |
| Glaxosmithkline, LLC. | $221.82 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Xeris Pharmaceuticals, INC. | $194.19 | 2022-2023 | Gvoke Hypopen |
| Lilly USA, LLC | $168.71 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $138.98 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $137.81 | 2024-2025 | Spravato |
| Exact Sciences Corporation | $124.31 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $83.37 | 2021-2024 | Trintellix |
| Insulet Corporation | $82.42 | 2025 | Omnipod |
| Lundbeck LLC | $82.02 | 2023-2025 | Rexulti |
| Dexcom, INC. | $69.95 | 2023-2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $55.29 | 2023-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $44.70 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $41.10 | 2023 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.50 | 2025 | Caplyta |
| Genentech USA, INC. | $32.14 | 2021 | |
| Nestle Healthcare Nutrition INC. | $31.12 | 2021 | |
| Phathom Pharmaceuticals, INC. | $26.55 | 2025 | Voquezna |
| Ultragenyx Pharmaceutical INC. | $24.43 | 2022 | |
| Sage Therapeutics, LLC | $23.37 | 2023 | |
| Edwards Lifesciences Corporation | $21.45 | 2023 | |
| Pfizer INC. | $18.55 | 2022 | |
| Sanofi Pasteur INC. | $16.65 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.40 | 2021 | |
| Medtronic, INC. | $14.79 | 2022 | |
| Amgen INC. | $14.62 | 2025 | Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $14.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kandice Burk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.